Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has issued an update.
Neuren Pharmaceuticals participated in the J.P. Morgan Healthcare Conference, highlighting its progress with NNZ-2591, a drug candidate moving into late-stage development for multiple indications following successful Phase 2 trials. The company is preparing for a Phase 3 trial for Phelan-McDermid syndrome and intends to advance other indications, while also working on non-clinical studies for undisclosed conditions. Additionally, its partner Acadia Pharmaceuticals shared plans to expand the market presence of DAYBUE in the US and Europe, potentially boosting Neuren’s market positioning and growth trajectory.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited is a company specializing in the development of drug therapies for serious neurological disorders that primarily affect early childhood, with a significant focus on conditions that have no or limited approved treatment options. Its key product, DAYBUE™ (trofinetide), is approved for the treatment of Rett syndrome, and the company is also advancing NNZ-2591, a drug candidate for multiple neurodevelopmental disorders.
YTD Price Performance: 4.78%
Average Trading Volume: 1,152
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $988.8M
For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.
